Skip to main content
PMC home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1993 Mar;36(2):76–82. doi: 10.1007/BF01754405

Cytokine regulation of cell-to-cell interactions in lymphokine-activated killer cell cytotoxicity in vitro

Toshiyuki Takahashi 1,2, Hiroshi Ishikura 1,✉, Kazuhiro Iwai 1,2, Chisa Takahashi 1, Hiroyuki Kato 2, Tatsuzo Tanabe 2, Takashi Yoshiki 1
PMCID: PMC11038514  PMID: 8093857

Abstract

The permanent pancreas carcinoma cell line, PCI-24, was developed in order to analyse cytokine regulation on pancreas carcinoma and lymphokine-activated killer (LAK) cell interaction. PCI cells expressed ICAM-1 and HLA-ABC, but not HLA-DR antigens. PCI cells showed augmented ICAM-1 and HLA-ABC expression when incubated with interferon γ (IFNγ) and tumour necrosis factor α. A similar but weak augmentary effect on the HLA-ABC and ICAM-1 surface expression was seen with interleukin-1β treatment. Natural attachment of LAK to PCI cells was augmented by recombinant IFNγ in close association with ICAM-1 up-regulation on PCI cells. In addition, natural attachment was significantly inhibited by anti-LFA-1 and anti-ICAM-1 antibody treatments. Cytotoxicity of the LAK cells against PCI cells was also significantly inhibited with the same treatment. Thus, the attachment of LAK cells to PCI cells through LFA-1/ICAM-1 molecules appeared to be essential for the cytotoxicity for PCI cells. Pretreatment of PCI cells, but not of LAK cells, with IFNγ or other cytokines resulted in a decrease of susceptibility for LAK cell cytotoxicity. The decreased susceptibility inversely correlated with HLA-ABC expression on the PCI cells. The collective evidence indicates that, although LAK cell attachment to pancreas carcinoma cells through the LFA-1/ICAM-1 molecule is augmented by IFNγ, IFNγ treatment of pancreas carcinoma cells reduces LAK cell cytotoxicity possibly through an increase in HLA-ABC or a regulation of molecules closely associated to HLA-ABC expression.

Key words: Pancreas cancer, LAK, IFNγ

References

  • 1.Barnstable CJ, Bodmer WF, Brown G, Galfre G, Milstein C, Williams AF, Ziegler A. Production of monoclonal antibodies to group A erythrocytes. HLA and other human cell surface antigens. New tools for genetic analysis. Cell. 1978;14:9–18. doi: 10.1016/0092-8674(78)90296-9. [DOI] [PubMed] [Google Scholar]
  • 2.Chervenak R, Wolcott RM. Target cell expression of MHC antigens is not (always) a turn-off signal to natural killer cells. J Immunol. 1988;140:3712–3716. [PubMed] [Google Scholar]
  • 3.De Fries RU, Golub SH. Characteristics and mechanism of IFN-γ-induced protection of human tumor cells from lysis by lymphokine-activated killer cells. J Immunol. 1988;140:3686–3693. [PubMed] [Google Scholar]
  • 4.Dustin ML, Rothlein R, Bhan AK, Dinarello CA, Springer TA. Induction by IL-1 and interferon-gamma: tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM-1) J Immunol. 1986;137:245–254. [PubMed] [Google Scholar]
  • 5.Dustin ML, Singer KH, Tuck DT, Springer TA. Adhesion of T lymphoblasts to epidermal keratinocytes is regulated by interferon-γ and is mediated by intercellular adhesion molecule 1 (ICAM-1) J Exp Med. 1988;167:1323–1340. doi: 10.1084/jem.167.4.1323. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Figdor CG, Kooyk YV, Keizer GD. On the mode of action of LFA-1. Immunol Today. 1990;11:277–280. doi: 10.1016/0167-5699(90)90112-m. [DOI] [PubMed] [Google Scholar]
  • 7.Gorelik E, Gunji Y, Herberman RB. H-2 antigen expression and sensitivity of BL6 melanoma cells to natural killer cell cytotoxicity. J Immunol. 1988;140:2096–2102. [PubMed] [Google Scholar]
  • 8.Ishikura H, Takahashi C, Kanagawa K, Hirata H, Imai K, Yoshiki T. Cytokine regulation of ICAM-1 expression on human renal tubular epithelial cells in vitro. Transplantation. 1991;51:1272–1275. doi: 10.1097/00007890-199106000-00024. [DOI] [PubMed] [Google Scholar]
  • 9.Kanagawa K, Ishikura H, Takahashi C, Tamatani T, Miyasaka M, Togashi M, Koyanagi T, Yoshiki T. Identification of ICAM-1-positive cells in the non-grafted and transplanted rat kidney: an immunohistochemical and ultrastructural study. Transplantation. 1992;52:1057–1062. doi: 10.1097/00007890-199112000-00022. [DOI] [PubMed] [Google Scholar]
  • 10.Kasahara M, Ikeda H, Ogasawara K, Ishikawa N, Okuyama T, Fukasawa Y, Kojima H, Kunikane H, Kawkin S, Ohhashi T, Natori T, Wakisaka A, Kikuchi Y, Aizawa M. Inhibition of autologous mixed lymphocyte reaction by monoclonal antibodies specific for the beta chain of HLA-DR antigens. Immunology. 1984;53:79–86. [PMC free article] [PubMed] [Google Scholar]
  • 11.Kotasek D, Vercellotti GM, Ochoa AC, Bach FH, White JG, Jacob HS. Mechanism of cultured endothelial injury induced by lymphokine-activated killer cells. Cancer Res. 1988;48:5528–5532. [PubMed] [Google Scholar]
  • 12.Lewis CE, McCracken D, Ling R, Richards PS, McCarthy SP, McGee JO. Cytokine release by single, immunophenotyped human cells: use of the reverse hemolytic plaque assay. Immunol Rev. 1991;119:23–39. doi: 10.1111/j.1600-065x.1991.tb00576.x. [DOI] [PubMed] [Google Scholar]
  • 13.Ljunggren HG, Karre K. Host resistence directed selectively against H-2 deficient lymphoma cells. J Exp Med. 1985;162:1745–1759. doi: 10.1084/jem.162.6.1745. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Lotze MT, Grimm EA, Mazumder A, Strausser JL, Rosenberg SA. Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. Cancer Res. 1981;41:4420–4425. [PubMed] [Google Scholar]
  • 15.Miyatake S, Kikuchi H, Oda Y, Nishioka T, Takahashi J, Kondoh S, Matsumoto M, Yamasaki T, Iwasaki K, Aoki T, Kasakura S, Namba Y. Decreased susceptibility of lined human gliosarcoma cells to lymphokine-activated killer cell cytolysis by γ-interferon treatment. Cancer Res. 1990;50:596–600. [PubMed] [Google Scholar]
  • 16.Mortarini R, Belli F, Parmiani G, Anichini A. Cytokine-mediated modulation of HLA-class II, ICAM-1, LFA-1, and tumor-associated antigen profile of melanoma cells. Comparison with antiproliferative activity by rIL-1β, rTNF-α, rIFN-γ, rIL-4, and their combinations. Int J Cancer. 1990;45:334–341. doi: 10.1002/ijc.2910450221. [DOI] [PubMed] [Google Scholar]
  • 17.Munn DH, Cheung NV. Interleukin-2 enhancement of monoclonal antibody-mediated celular cytotoxicity against human melanoma. Cancer Res. 1987;47:6600–6605. [PubMed] [Google Scholar]
  • 18.Naganuma H, Kiessling R, Patarroyo M, Hansson M, Handgretinger R, Gronberg A. Increased susceptibility of IFN-γ-treated neuroblastoma cells to lysis by lymphokine-activated killer cells: Participation of ICAM-1 induction on target cells. Int J Cancer. 1991;47:527–532. doi: 10.1002/ijc.2910470410. [DOI] [PubMed] [Google Scholar]
  • 19.Piontek GE, Taniguchi K, Ljunggren HG, Groneberg A, Kiessling R, Klein G, Karre K. YAC-1 MHC class I variants reveal an association between decreased NK sensitivity and increased H-2 expression after interferon treatment or in vivo passage. J Immunol. 1985;135:4281–4288. [PubMed] [Google Scholar]
  • 20.Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan M, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG, White DE. A progress report on the treatment of 157 patients with advanced cancer using LAK cells and IL-2 or high-dose IL-2 alone. N Engl J Med. 1987;316:889–897. doi: 10.1056/NEJM198704093161501. [DOI] [PubMed] [Google Scholar]
  • 21.Rosenstein M, Yron I, Kaufmann Y, Rosenberg SA. Lymphokine-activated killer cells: lysis of fresh syngeneic natural killer-resistent murine tumor cells by lymphocytes cultured in interleukin 2. Cancer Res. 1984;44:1946–1953. [PubMed] [Google Scholar]
  • 22.Shiloni E, Eisenthal A, Sachs D, Rosenberg SA. Antibody-dependent cellular cytotoxicity mediated by murine lymphocytes activated in recombinant interleukin 2. J Immunol. 1987;138:1992–1998. [PubMed] [Google Scholar]
  • 23.Simmons D, Makgoba MW, Seed B. ICAM, an adhesion ligand of LFA-1, is homologous to the neural cell adhesion molecule NCAM. Nature. 1988;331:624–627. doi: 10.1038/331624a0. [DOI] [PubMed] [Google Scholar]
  • 24.Staunton DE, Dustin ML, Springer TA. Functional cloning of ICAM-2, a cell adhesion ligand for LFA-1 homologous to ICAM-1. Nature. 1989;339:61–64. doi: 10.1038/339061a0. [DOI] [PubMed] [Google Scholar]
  • 25.Storkus WJ, Howell DN, Salter RD, Dawgon JR, Cresswell P. NK susceptibility varies inversely with target cell class I HLA antigen expression. J Immunol. 1988;138:1657–1659. [PubMed] [Google Scholar]
  • 26.Stotter H, Wiebke EA, Tomita S, Belldegrun A, Topalian S, Rosenberg SA, Lotze MT. Cytokines alter target cell susceptibility to lysis: II. Evaluation of tumor infiltrating lymphocytes. J Immunol. 1989;142:1767–1773. [PubMed] [Google Scholar]
  • 27.Tabibzadeh SS, Poubouridis D. Expression of leukocyte adhesion molecules in human endometrium. Am J Clin Pathol. 1990;93:183–189. doi: 10.1093/ajcp/93.2.183. [DOI] [PubMed] [Google Scholar]
  • 28.Takahashi K, Nakamura T, Koyanagi M, Kato K, Hashimoto Y, Yagita H, Okumura K. A murine very late activation antigenlike extracellular matrix receptor involved in CD2- and lymphocyte function-associated antigen-1-independent killer-target cell interaction. J Immunol. 1990;145:4371–4379. [PubMed] [Google Scholar]
  • 29.Taylor RS, Griffiths CE, Brown MD, Swanson NA, Nickoloff BJ. Constitutive absence and interferon-gamma-induced expression of adhesion molecules in basal cell carcinoma. J Am Acad Dermatol. 1990;22:721–726. doi: 10.1016/0190-9622(90)70097-2. [DOI] [PubMed] [Google Scholar]
  • 30.Tsujisaki M, Imai K, Hirata H, Hanzawa Y, Masuya J, Nakano T, Sugiyama T, Matsui M, Hinoda Y, Yachi A. Detection of circulating intercellular adhesion molecule-1 antigen in malignant diseases. Clin Exp Immunol. 1991;85:3–8. doi: 10.1111/j.1365-2249.1991.tb05673.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Vogetseder W, Feichtinger H, Schulz TF, Schwaeble W, Tabaczewski P, Mitterer M, Bock G, Marth C, Dapunt O, Mikuz G, Dierich MP. Expression of 7F7-antigen, a human adhesion molecule identical to intercellular adhesion molecule-1 (ICAM-1) in human carcinomas and their stromal fibroblasts. Int J Cancer. 1989;43:768–773. doi: 10.1002/ijc.2910430504. [DOI] [PubMed] [Google Scholar]
  • 32.West WH, Tauer KW, Yannelli JR, Marshall GD, Orr DW, Thurman GB, Oldham RK. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advenced cancer. N Engl J Med. 1987;316:898–905. doi: 10.1056/NEJM198704093161502. [DOI] [PubMed] [Google Scholar]
  • 33.Wuthrich RP, Jevniker AM, Takei F, Glimcher LH, Kelley VE. Intercellular adhesion molecule-1 (ICAM-1) expression is upregulated in autoimmune murine lupus nephritis. Am J Pathol. 1990;136:441–450. [PMC free article] [PubMed] [Google Scholar]
  • 34.Xiao J, Brahmi Z. Target cell-directed inactivation and IL-2-dependent reactivation of LAK cells. Cell Immunol. 1989;122:295–306. doi: 10.1016/0008-8749(89)90078-6. [DOI] [PubMed] [Google Scholar]
  • 35.Yron I, Wood TA, Spiess PJ, Rosenberg SA. In vitro growth of murine T cells. V. The isolation and growth of lymphoid cells infiltrating syngeneic solid tumors. J Immunol. 1980;125:238–245. [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES